← Companies
Biohaven Ltd.
Data as of Sep 17, 2026
BHVN
CIK 1935979Lobbying
$620,000 in reported federal lobbying spend across 11 quarterly filings, most recently Jul 20, 2026. Amounts are the sums companies and their registrants report on Lobbying Disclosure Act filings; a filing that covers several issues counts its full amount under each.
Spend by issue
- Health Issues$420K8 filings
- Health Issues +2$120K2 filings
- Medical/Disease Research/Clinical Labs +2$80K1 filing
Latest filings, Jan 2026 onward
| Filed | Registrant and subject | Amount |
|---|---|---|
| Jul 20, 2026 | DLA PIPER LLP (US) for BIOHAVEN PHARMACEUTICALS INC. Health Issues Policies related to drug approval for treatment of rare diseases. Regulatory flexibilities afforded to neurodegenerative diseases as provided for in the Act of ALS. | $60,000 |
| Jul 17, 2026 | CHECKMATE GOVERNMENT RELATIONS for BIOHAVEN LTD. Health Issues · Medical/Disease Research/Clinical Labs · Pharmacy Advocacy related to patients with rare diseases
Advocacy related to patients with rare diseases
Advocacy related to patients with rare diseases | $120,000 |
| Apr 20, 2026 | DLA PIPER LLP (US) for BIOHAVEN PHARMACEUTICALS INC. Health Issues Policies related to drug approval for treatment of rare diseases. Regulatory flexibilities afforded to neurodegenerative diseases as provided for in the Act of ALS. | $60,000 |
| Apr 19, 2026 | CHECKMATE GOVERNMENT RELATIONS for BIOHAVEN LTD. Medical/Disease Research/Clinical Labs · Pharmacy · Health Issues Advocacy related to patients with rare diseases
Advocacy related to patients with rare diseases
Advocacy related to patients with rare diseases | $80,000 |
| Feb 24, 2026 | CHECKMATE GOVERNMENT RELATIONS for BIOHAVEN LTD. Health Issues · Medical/Disease Research/Clinical Labs · Pharmacy Issues relating to rare diseases
Issues relating to rare diseases
Issues relating to rare diseases | $0 |
| Jan 16, 2026 | DLA PIPER LLP (US) for BIOHAVEN PHARMACEUTICALS INC. Health Issues Policies related to drug approval for treatment of rare diseases. Regulatory flexibilities afforded to neurodegenerative diseases as provided for in the Act of ALS. | $60,000 |